Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for FY 2025-26
Regulatory Filings Classification · 92% confidence The document is an Annual Secretarial Compliance Report submitted under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations. It is an attestation by Company Secretaries reviewing statutory compliance and is primarily a compliance certificate/legally required submission to stock exchanges. It does not contain substantive financial statements, but rather confirms adherence to SEBI regulations. Under the certification rule, such officer certifications or compliance documents are classified as Regulatory Filings (RNS).
2026-05-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 75% confidence The document is a notice to the stock exchanges (BSE and NSE) announcing an upcoming Q4FY26 earnings call to discuss audited financial results. It does not contain any financial data or the results themselves, nor does it enclose the actual report. It is not a transcript, presentation, or report publication notice, but rather a general regulatory announcement of a conference call event. Therefore, it best fits the fallback category of Regulatory Filings (RNS).
2026-05-21 English
Q4FY26 Audited Financial Results Earnings Call
Regulatory Filings Classification · 65% confidence The document is a formal exchange filing from Natco Pharma to BSE and NSE announcing the schedule and dial‐in details for an upcoming earnings call to discuss the audited Q4 FY26 results. It contains no financial data, highlights, or the results themselves, and is not a transcript. It is not a report but a regulatory announcement about a corporate event. Therefore it falls into the fallback “Regulatory Filings” category.
2026-05-21 English
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve considering Audited Financial ....
Regulatory Filings Classification · 88% confidence The document is a stock exchange notice titled “Intimation of Board Meeting,” advising on the date for the board’s consideration of audited financial results. It does not contain actual financial results or management commentary; nor does it announce director appointments or resignations. It is a mandatory regulatory announcement to exchanges. Hence it falls under the general “Regulatory Filings” category (RNS).
2026-05-18 English
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
Legal Proceedings Report Classification · 85% confidence The document is a formal disclosure submitted to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regarding receiving a demand notice from the National Pharmaceutical Pricing Authority and details of alleged overcharging. It is a regulatory/legal matter update, not an annual or interim report, earnings release, or dividend announcement. This aligns with the Legal Proceedings Report category as it concerns a regulatory action and demand notice.
2026-05-15 English
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Legal Proceedings Report Classification · 95% confidence The document is a SEBI Listing Obligations disclosure under Regulation 30 announcing receipt of a demand notice from the National Pharmaceutical Pricing Authority. It reports a regulatory/legal action rather than financial results, board changes, or shareholder matters. This fits “Legal Proceedings Report” (LTR) as it details a regulatory order and its impact.
2026-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.